Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pfizer (PFE)

Pfizer reaffirms 2026 guidance, $59.5B-$62.5B revenue, after CFO transition news

Neutral Impact 4 of 5 guidance Written later

Pfizer said on June 18, 2026 that it is reaffirming all components of its full-year 2026 guidance, following its announcement of a Chief Financial Officer transition the same day. The guidance includes revenues of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, unchanged from the December 16, 2025 guidance and the May 5, 2026 reaffirmation.

Key points

  • Full-year 2026 revenue guidance reaffirmed at $59.5 billion to $62.5 billion
  • Adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00
  • Guidance first issued December 16, 2025 and reaffirmed May 5, 2026 on the first quarter earnings call
  • Filing follows a Chief Financial Officer transition announcement made June 18, 2026

The filing

CompanyPfizer (PFE)
Form8-K, current report
Filed with the SECJun 18, 2026, 1:17 PM ET
Accession number0000078003-26-000087

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.